EGS 2025 places MIGS mainly in early to moderate open-angle glaucoma with modest pressure and drop reduction; trabeculectomy remains the strongest option for low targets and advanced disease. HORIZON supports Hydrus with cataract surgery in a defined primary open-angle glaucoma population, not a universal MIGS ranking.
Terminology and draft status
Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.
01Start with the target pressure, not the device
Combined cataract and glaucoma surgery is a plan, not a package. Phacoemulsification repairs the visual problem caused by the lens, while a minimally invasive glaucoma procedure aims to lower intraocular pressure (IOP) or reduce eye drops. The two effects are different, and one does not prove the other. 1 2
The 2025 European Glaucoma Society (EGS) guidance separates the decision by target pressure. When IOP is at or near target in early or moderate open-angle glaucoma, phacoemulsification alone or phacoemulsification with MIGS is recommended. When IOP is clearly above target, a glaucoma intervention is offered, and bleb-forming surgery with or without phacoemulsification is advised. 2
Target pressure comes first. In advanced glaucoma, EGS identifies trabeculectomy as the most effective operation for a low target, and MIGS is not usually indicated. The guideline also notes that trabeculectomy is more effective than MIGS for lowering IOP, with high certainty for trabeculectomy and low certainty for stand-alone MIGS. 2
Cataract surgery alone can lower IOP modestly in open-angle glaucoma, particularly with pseudoexfoliation or a higher starting pressure. Before adding surgery, record the target, drops and previous operations and examine the angle by gonioscopy; poorly controlled glaucoma needs its own pressure strategy. 2
02The lifelong glaucoma journey and the ocular surface
Glaucoma is a lifelong disease, and the ocular surface carries the cost of years of drops. Preservatives such as benzalkonium chloride (BAK), active drugs and chronic inflammation can cause hyperaemia, meibomian gland dysfunction and conjunctival change. This can make later filtering surgery more difficult. 1
The original lecture says every long-term patient develops ocular surface disease. That absolute is not supported: ocular surface disease is common and important, but it is not inevitable in every person, and its severity varies. 1
Prostaglandin-associated periorbitopathy is a recognised effect of long-term prostaglandin analogues. Orbital fat atrophy, a deeper upper lid sulcus and enophthalmos can occur, but they are not universal and may be reversible after stopping the drug. The original statement that atrophy always follows is too strong. 1
A deep-set eye makes draping and eyelash isolation harder. That matters for endophthalmitis prevention, but it is a practical caution rather than a surgical rule. Check the ocular surface, lids and conjunctiva before surgery and plan the exposure. 1
03Cataract surgery after trabeculectomy
After trabeculectomy, aqueous can reach the bleb through the iridectomy and sclerostomy. The original “pupil bypass” describes altered flow; it proves neither complete bypass nor the cause of every posterior synechia or small rigid pupil. Assess those findings individually. 1
The original recommends waiting 12 months, with a minimum of 6 months, after trabeculectomy, and says surgery within 6 months triples bleb failure. The 12-month and 6-month figures and the threefold risk were not verified in the handed-off sources. Treat them as a historical opinion and individualise timing with the glaucoma surgeon. 1
A temporal incision is often chosen to avoid a superior bleb, but it is not mandatory in every eye. The choice depends on the bleb position, exposure, astigmatism and the surgeon's view. 1
Iris hooks can help in a shallow chamber or a rigid pupil, but they are not automatically better than pupil expander rings. Synechiolysis should be gentle and used as needed; excessive force risks iris damage and bleeding. 1
Trypan blue helps visualise the capsule. The original also uses blue staining of the bleb under pressure as a flow test. That test has not been validated as proof of patency, so do not rely on it alone. Routine subconjunctival 5-fluorouracil (5-FU) at the end of every case is also not supported for all eyes; it is an individual adjunct. 1
04Classify MIGS by outflow route
MIGS means minimally invasive glaucoma surgery, aiming for limited trauma and rapid recovery; the original Ahmed attribution is unverified and safety remains procedure-specific. Distinguish trabecular/Schlemm canal, suprachoroidal and subconjunctival outflow before comparing benefits and risks. 2
Trabecular MIGS and bleb-forming minimally invasive bleb surgery (MIBS, also called MIPS) are not interchangeable. Bleb-forming procedures can lower pressure more but need mitomycin C (MMC), a bleb and long-term bleb care. Calling every small device MIGS hides that difference. 2
A suprachoroidal implant is not automatically as safe as another suprachoroidal implant. The CyPass experience showed that device-specific design and follow-up matter. MINIject must be judged on its own data, not on the assumption that the route guarantees safety. 1 2
05Trabecular devices: iStent, Hydrus, OMNI and GATT
The iStent and iStent inject/W create a bypass through the trabecular meshwork. Blood reflux after lowering the anterior chamber pressure can support patency, but it is not proof that the device sits in the ideal position. The original calls reflux a safe sign; it is a useful clue, not a guarantee. 1
Hydrus is a nitinol scaffold in Schlemm's canal. The original calls it an 8-mm device that opens the canal for 3 hours. The 3 hours means three clock hours, roughly 90 degrees of arc, not three hours of surgery. Current exact dimensions and the instructions for use still need checking. 1 2
HORIZON randomised 369 eyes to Hydrus with cataract surgery and 187 to cataract surgery alone. Participants had cataract and primary open-angle glaucoma, used at least one medicine, had washed-out diurnal IOP of 22 to 34 mmHg and had no previous incisional glaucoma surgery. Randomisation was 2:1 after phacoemulsification, and 80% completed 5 years. 3
At 5 years, 49.5% of the Hydrus group reached IOP 18 mmHg or less without medicines versus 33.8% of controls (p = 0.003). A 20% or greater reduction occurred in 54.2% versus 32.8%, mean medicines were 0.5 ± 0.9 versus 0.9 ± 0.9, and 66% versus 46% were drop-free. Incisional glaucoma surgery was less frequent, 2.4% versus 6.2% (p = 0.027). 3
The endothelial cell loss rate from 3 to 60 months did not differ significantly (p = 0.261); this does not establish equal rare-event safety. The selected population, 20% missing 5-year data and sponsor context awaiting full appraisal limit extrapolation to advanced disease and other procedures; trabeculectomy was not a comparator. 3
OMNI combines viscodilation with trabeculotomy; it is not simply a suture operation, and it is a single-use device with its own cost. GATT uses a 5-0 or 6-0 Prolene suture or a catheter to open 360 degrees. The original calls GATT a 5-euro alternative; that figure is not the total cost of surgery, staffing or follow-up, and the price contrast with OMNI is not a full economic comparison. A particular advantage in pigmentary glaucoma is plausible but unproven. 1 2
The original quotes 20 to 30% pressure reduction for GATT and OMNI. The populations and comparators behind that range are not identified. Do not use it to rank these operations against Hydrus, iStent or trabeculectomy. 1
06ECP, CyPass and bleb-forming MIBS
Endoscopic cyclophotocoagulation (ECP) reduces aqueous production by coagulating the ciliary processes. The original gives about 15% reduction alone and up to 35% when combined with iStent as Ice-Combined. Those figures come from selected settings, not a head-to-head trial, and the combined name should not imply a validated additive effect. 1
ECP works on production, while trabecular MIGS works on outflow. That difference matters when choosing a procedure, but it does not prove that one is better for a given eye. 1
A transient hyphaema is common after ab-interno surgery. It can be a sign of flow, but it is not automatically good or harmless. Check the pressure, the chamber and the view, and look for a complication rather than assuming the blood is benign. 1
CyPass was withdrawn in 2018 over endothelial cell loss concerns. The original 30% at 5 years and proximity to the endothelium remain an incompletely appraised COMPASS XT attribution, not a uniform loss rate for all patients; device model and position belong in the safety assessment. 1
Xen and PreserFlo are bleb-forming subconjunctival procedures. They can lower pressure strongly, but they require MMC or another antifibrotic strategy and ongoing bleb care. They are not interchangeable with trabecular MIGS. 2
MINIject targets the suprachoroidal space. The route is shared with CyPass, but the implant, trial population and follow-up are different. Safety and effectiveness must be judged separately. 2
07Read the table without turning it into a ranking
The table summarises the six original rows with their numbers, but it is a revision aid, not a ranking. Each row now carries the main limitation: selected populations, indirect comparisons, withdrawal history or unverified routine steps. 1 2 3
The strongest randomised evidence in this lecture is HORIZON for Hydrus. It supports a modest advantage in a defined primary open-angle glaucoma population. It does not show that Hydrus is better than trabeculectomy, that every MIGS device works the same way, or that medication freedom is guaranteed. 3
After combined surgery, watch for a flat or shallow anterior chamber, wound leak, raised IOP, hyphaema, inflammation, cystoid macular oedema and signs of endophthalmitis. Severe pain, marked visual loss, a hard eye or a red, painful eye after surgery needs urgent review. 1
Document the target pressure, the procedure, the device, the viscoelastic used, the bleb status and the plan for drops. The original promises medication freedom and ocular surface protection. Those are possible goals, not guaranteed outcomes, and the patient should hear that difference. 1
| Procedure or device | Anatomical target | Evidence and IOP lowering | Specific advantage | Revision point and limitation |
|---|---|---|---|---|
| iStent inject | Trabecular meshwork | About 1 fewer medicine in the original summary; not a head-to-head ranking. | Favourable safety profile in selected eyes, not an absolute highest safety. | Blood reflux supports patency but does not prove ideal placement. |
| Hydrus | Schlemm's canal | 5-year HORIZON data; 49.5% versus 33.8% reached IOP 18 mmHg or less without medicine. | Scaffolding of about 90 degrees, described as 3 clock hours. | The original says inferonasal placement; the nasal angle is not universally inferonasal. Exact current IFU pending. |
| GATT or OMNI | Trabecular meshwork | 20 to 30% lowering in the original, from unidentified populations and comparators. | Stentless; GATT can be cost-effective. | OMNI is viscodilation plus trabeculotomy, not all suture; GATT uses 5-0 or 6-0 Prolene or a catheter for 360 degrees. |
| ECP | Ciliary processes | 15% alone or 35% in the Ice-Combined description; not a head-to-head trial. | Reduces aqueous production by a distinct mechanism. | The numbers are not a device ranking; caution with uveitis because of cystoid macular oedema risk. |
| CyPass | Suprachoroidal space | Withdrawn from the market in 2018 after endothelial cell loss concerns. | Historical relevance for suprachoroidal device safety. | The original gives 30% endothelial loss at 5 years; this was not uniform for all patients or devices. Full COMPASS XT unread. |
| PreserFlo or Xen | Subconjunctival space | Bleb-forming MIBS or MIPS, close in concept to trabeculectomy but not equivalent. | Strong pressure-lowering potential. | Requires mitomycin C and bleb care; not interchangeable with trabecular MIGS. |
What are the main learning points?
Start with the target pressure and glaucoma stage. EGS 2025 supports phacoemulsification alone or with MIGS when pressure is at or near target in early to moderate open-angle glaucoma, and favours bleb-forming surgery when pressure is clearly above target. HORIZON supports Hydrus with cataract surgery in a defined primary open-angle glaucoma population, not a universal device ranking.
When is assessment urgent?
Sudden visual loss, severe pain, a hard eye, new field loss, wound leak, a flat anterior chamber or suspected endophthalmitis after surgery needs immediate ophthalmic assessment. Do not change glaucoma medicines or plan surgery from this educational text.
References and access status
- 1Immutable original export; combined cataract and MIGS study guide
Complete export read. Original attribution, recording and transcript were not independently verified.
- 2European Glaucoma Society terminology and guidelines for glaucoma, 6th edition, 2025. DOI 10.1136/bjophthalmol-2025-egsguidelines
Printed pages 22 and 23, questions 5 to 8, reread 14 November 2026; selected MIGS section also located. Not the full book or device instructions for use.
- 3HORIZON 5-year results of a Schlemm canal microstent with cataract surgery. PMID 35218867
Complete NCBI abstract reread 14 November 2026. Full report, protocol and supplements unread; sponsor context and missing 5-year data retained as limits.
Original lecture link
- Original exported lecture link
Export link only; recording, transcript and speaker attribution not independently checked.
For patients
Combined surgery can address a cataract and glaucoma at the same time, but it is not automatically better for every eye. The target pressure, the angle and any earlier glaucoma operation guide the choice.
The aim may be fewer drops or a lower pressure, but success is not guaranteed and follow-up remains necessary. Some eyes still need drops or another operation.
After surgery, sudden visual loss, severe pain, a hard eye, new field loss, a wound leak or a painful red eye needs immediate assessment. This text cannot replace your own examination.
Sudden visual loss, severe pain, a hard eye, new field loss, wound leak, a flat anterior chamber or suspected endophthalmitis after surgery needs immediate ophthalmic assessment. Do not change glaucoma medicines or plan surgery from this educational text.